Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer

BACKGROUND: Monthly goserelin 3.6 mg dosing suppresses estradiol (E2) production and has proven efficacy in pre-menopausal women with estrogen receptor (ER)-positive breast cancer. This non-inferiority study evaluated the efficacy and safety of 3-monthly goserelin 10.8 mg compared with monthly goser...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Shinzaburo, Kim, Hee Jeong, Jesena, Anita, Parmar, Vani, Sato, Nobuaki, Wang, Hwei-Chung, Lokejaroenlarb, Santi, Isidro, Jofel, Kim, Ku Sang, Itoh, Yohji, Shin, Eisei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999470/
https://www.ncbi.nlm.nih.gov/pubmed/26350351
http://dx.doi.org/10.1007/s12282-015-0637-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999470/
https://www.ncbi.nlm.nih.gov/pubmed/26350351
http://dx.doi.org/10.1007/s12282-015-0637-4

Ejemplares similares